Tag Archives: CD19 x CD20 CAR-T

JNJ / AbelZeta and Mustang Bio Present Clinical Updates from their Assets Targeting CD20 in NHL; ASH 2023 Analysis 5

ASH 2023 Analysis 5: JNJ / AbelZeta and Mustang Bio presented clinical updates from assets targeting CD20 in NHL. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

You May Have Missed: CARsgen Partners with Moderna; AZ to Collaborate in the Development of a New CAR-T in Solid Tumors; Gilead to Evaluate Novel Dual CAR-T; Poseida and Roche Publish P-CD19CD20-ALLO1’s New Trial; Germany’s G-BA Completes Carvykti’s Reimbursement – August 2023 Recap (Blast 1/2)

In August 2023, the Celltelligence team detected several relevant news items that were not discussed in individual blasts but are also worth highlighting. Celltelligence will publish a two-part series discussing the news and providing insights about their importance in the cell therapy space. In this first summary, the following topics are covered:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

The FDA Clears Poseida’s P-CD19CD20-ALLO1 IND in B-Cell Malignancies

On Wednesday, July 5, Poseida announced (press release) that the FDA has approved the IND for P-CD19CD20-ALLO1 (allogeneic CD19 x CD20 dual CAR-T) in B-cell malignancies. Below, Celltelligence provides insights on P-CD19CD20-ALLO1’s IND clearance while discussing the potential competition that P-CD19CD20-ALLO1 could face.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

JNJ to Invest in CAR-T Therapies for Lymphoma

On Tuesday, May 2, JNJ announced (press release) a WW agreement with Cellular Biomedicine Group (CBMG) for the development, manufacturing, and commercialization of two novel cell therapies, C-CAR039 (prizloncabtagene autoleucel; CD20 x CD19 CAR-T) and C-CAR066 (CD20 CAR-T) for the treatment of B-cell malignancies. Below, Celltelligence provides insights on JNJ’s cell therapy pipeline extension and new interest in the lymphoma space while discussing its potential direct competitors in the space.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Novartis, CRISPR Tx, and Miltenyi Report Clinical Updates from Their New Assets in Lymphomas; ASH 2022 Analysis 5

ASH 2022 Analysis 5: Novartis, CRISPR Tx, and Miltenyi presented clinical updates from their cell therapies in lymphoma. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below:

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

FDA Accepts Gilead’s KITE-363 (CD19 x CD20 CAR-T) IND in LBCL

On Thursday, August 19, Gilead (Kite) announced (press release) that the FDA has accepted the IND for KITE-363 (CD19 x CD20 CAR-T) in LBCL. Below, Celltelligence provides details on KITE-363’s IND application while discussing potential competition KITE-363 may face upon approval.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

New Gilead KITE-363 (CD19 x CD20 CAR-T) Ph1 Trial in R/R BCL Posted

On Wednesday, August 4, a new Gilead (Kite) Ph1 trial evaluating KITE-363 (autologous CD19 x CD20 CAR-T) in r/r B cell lymphoma (BCL) was observed on CT.gov. Below, Celltelligence provides details for this trial while discussing the significance of Gilead (Kite) developing a dual-targeting CAR-T.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Results from Kymriah’s Ph2 ELARA Trial; When Could Kymriah Become Approved in FL? Is Retreatment With Yescarta Commercially Feasible? CBMG Highlights Results From C-CAR066 and C-CAR039; ASCO 2021 Day 3 Part II

On the third day of ASCO 2021, five key clinical updates were presented from Novartis, Gilead, and CBMG. Below, Celltelligence provides insights and context for each presentation.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.